From major journals, first or last author from the Institute for Cancer Research
Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM(2022) Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials J Immunother Cancer, 10(5) DOI 10.1136/jitc-2021-004345, PubMed 35613827
Skotland T, Iversen TG, Llorente A, Sandvig K(2022) Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges Adv Drug Deliv Rev, 186, 114326(in press) DOI 10.1016/j.addr.2022.114326, PubMed 35588953
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Smirnov P, Smith I, Safikhani Z, Ba-Alawi W, Khodakarami F, Lin E, Yu Y, Martin S, Ortmann J, Aittokallio T, Hafner M, Haibe-Kains B(2022) Evaluation of statistical approaches for association testing in noisy drug screening data BMC Bioinformatics, 23(1), 188 DOI 10.1186/s12859-022-04693-z, PubMed 35585485
Ianevski A, Giri AK, Aittokallio T(2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples Nucleic Acids Res(in press) DOI 10.1093/nar/gkac382, PubMed 35580060
Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI(2022) In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis Mol Oncol(in press) DOI 10.1002/1878-0261.13225, PubMed 35574900